By Industry News
Miami, FL – November 10, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company that specializes in the clinical application of human birth tissue-based products, announced today that it had joined forces with key stakeholder groups around the nation who are advocating for diabetes awareness and optimal patient care, especially in chronic, debilitating conditions like late stage (Wagner Grade 3 and 4) Complex Diabetic Foot Ulcers (DFUs). Amniox has rolled out a month-long virtual campaign, #DFUAvengers, targeting health care professionals who treat patients living with chronic wounds.
Health care professionals can learn about the NEOX family of Cryopreserved Umbilical Cord Allografts at the SAWC Fall Virtual Meeting 2020 from November 4 - 6, and at the WoundCon Fall 2020 Virtual Conference and Exhibition on November 13, 2020. NEOX wound allografts support regenerative healing and functional recovery for late stage and chronic wounds with higher closure rates, fewer applications, and reduced cost of care.1
People with diabetes mellitus are at substantial risk of developing a foot ulcer at some point in their lifetime. Unlike other types of deep wounds, DFUs typically exhibit delayed healing and a downstream consequence of prolonged high levels of glucose in the blood. This can trigger a wide range of molecular events leading to damage of the nerves, blood vessels, tissues, and organs. Damage to blood vessels can increase the risk of heart attack and stroke, and nerve damage can lead to eye damage or kidney damage.2
“A cornerstone of this campaign is peer-to-peer education. #DFUAvengers will afford clinicians several opportunities to learn how our cryopreserved umbilical cord allograft, NEOX, is used as an adjunct therapy to expedite wound healing,” said TissueTech co-founder Amy Tseng, MBA, CEO, and President.
Amniox Medical invites all wound care professionals to a live webinar on Wednesday, November 18, 2020, from 8:30pm – 9:30pm, EST. Umbilical Cord Allograft Applications in Limb Salvage will be presented by Jacob Wynes, DPM and Thomas Fusco, DPM, FACFAS. There is no cost to participate. Click here to register.
Amniox also proudly supports the Centers for Disease Control and Prevention’s (CDC) National Diabetes Prevention Program that addresses the increasing burden of prediabetes and type 2 diabetes in the United States. This program offers evidence-based, cost-effective interventions that help prevent type 2 diabetes. You can refer your at-risk patients to a CDC-recognized lifestyle change program proven by research to cut their risk of type 2 diabetes by more than half. Participating in this program will encourage weight loss and other healthy changes to your patients’ lifestyles, lowering their risk of type 2 diabetes, heart attack, and stroke.
For a complete schedule of #DFUAvengers virtual activities, visit the Amniox website.
About Amniox Medical, Inc.
AMNIOX® Medical, Inc. is the first provider of a cryopreserved matrix comprised of human umbilical cord that can be stored in a refrigerator for up to two years and is ready to use without thawing, transplanting the benefits of regenerative healing for non-healing and chronic wounds.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., is a scientific and market leader in the field of regenerative medicine.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.
1. An open‐label trial of cryopreserved human umbilical cord in the treatment of complex diabetic foot ulcers complicated by osteomyelitis; William A. Marston MD John C. Lantis 2nd MD Stephanie C. Wu DPM Aksone Nouvong DPM Tommy D. Lee MSHS Nicholas D. McCoy BS Herbert B. Slade MD Scheffer C. Tseng MD, PhD; first published: 03 August 2019 https://doi.org/10.1111/wrr.12754
2. Park S, Kang HJ, Jeon JH, Kim MJ, Lee IK. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019; 42(3): 252‐ 262.